News

Ketamine and hypertension - Kata Canada

Ketamine and Hypertension

Ketamine produces a sympathomimetic response, typically leading to tachycardia and hypertension. Most often this elevation is modest, in keeping with light exercise. Concerns have been raised that ketamine therapy should be denied to those with hypertension, or those with cardiovascular risk factors. Some physicians advocate for the emergent treatment of ketamine associated hypertension (KIH) when it occurs during Ketamine Assisted Therapy (KAT).

Read More »
guidance and teaching for Kata Canada

Guidance on the use of Ketamine, How do Alberta and Saskatchewan Compare

Earlier this year, the associations governing medical doctors in both Saskatchewan (CPSS) and Alberta (CPSA) released information regarding their positions on the use of ketamine for off-label treatments, including chronic pain and a variety of mental health conditions. The CPSS issued a letter to an MD in January, 2021, and the CPSA released a Clinical Toolkit in May, 2021.

Read More »
A red headed woman relaxing in the grass

Non-IV Ketamine Permitted in Community Settings in BC

A statement and interim guidance from the College and Physicians and Surgeons of BC (CPSBC) on ketamine administration in the community, was released August 10, 2021. The interim guidelines stem from a lengthy and ongoing process of consultation and negotiation to shape the clinical use of ketamine for mental health conditions and chronic pain in British Columbia.

Read More »
Breastfeeding mother with her child

New Study Shows Safe Levels of Ketamine in Breast Milk

A recently published study The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of ketamine and metabolites is the first study conducted on this subject providing data that supports the safety of ketamine administration for the treatment of postpartum depression (PPD) and other emotional disorders during breastfeeding.

Read More »
Ketamine and hypertension - Kata Canada
oelfar

Ketamine and Hypertension

Ketamine produces a sympathomimetic response, typically leading to tachycardia and hypertension. Most often this elevation is modest, in keeping with light exercise. Concerns have been raised that ketamine therapy should be denied to those with hypertension, or those with cardiovascular risk factors. Some physicians advocate for the emergent treatment of ketamine associated hypertension (KIH) when it occurs during Ketamine Assisted Therapy (KAT).

Read More »
guidance and teaching for Kata Canada
Madison Nobbs

Guidance on the use of Ketamine, How do Alberta and Saskatchewan Compare

Earlier this year, the associations governing medical doctors in both Saskatchewan (CPSS) and Alberta (CPSA) released information regarding their positions on the use of ketamine for off-label treatments, including chronic pain and a variety of mental health conditions. The CPSS issued a letter to an MD in January, 2021, and the CPSA released a Clinical Toolkit in May, 2021.

Read More »
A red headed woman relaxing in the grass
Madison Nobbs

Non-IV Ketamine Permitted in Community Settings in BC

A statement and interim guidance from the College and Physicians and Surgeons of BC (CPSBC) on ketamine administration in the community, was released August 10, 2021. The interim guidelines stem from a lengthy and ongoing process of consultation and negotiation to shape the clinical use of ketamine for mental health conditions and chronic pain in British Columbia.

Read More »
Breastfeeding mother with her child
Madison Nobbs

New Study Shows Safe Levels of Ketamine in Breast Milk

A recently published study The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of ketamine and metabolites is the first study conducted on this subject providing data that supports the safety of ketamine administration for the treatment of postpartum depression (PPD) and other emotional disorders during breastfeeding.

Read More »
Madison Nobbs

World psychedelics day presenting sponsor

World psychedelics day presenting sponsor (6-20) June 20th, 2021 marks the first inaugural World Psychedelics Day! We are proud presenting sponsors of this event and cannot wait for to hear from the array of industry leading scientists, doctors, visionaries &

Read More »

KATA Canada announces new Executive Director

For immediate public release KATA Canada announces new Executive Director KATA Canada is pleased to announce that the Board has approved the appointment of Madison Nobbs to the role of Executive Director of KATA Canada. Congratulations! She has been with

Read More »
Categories